Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)

Delayed Quote. Delayed  - 09/26 05:35:18 pm
11.53 EUR   -1.87%
09/15 ABLYNX : 15/09/2016 ablynx receives transparency notification from o..
09/15 ABLYNX : Receives transparency notification from oppenheimer funds, ..
09/06 ABLYNX : 06/09/2016 ablynx receives transparency notification from g..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ABLYNX (D) : ABLYNX ANNOUNCES WARRANT EXERCISE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/23/2012 | 07:17pm CEST
ABLYNX ANNOUNCES WARRANT EXERCISE GHENT, Belgium, 23 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced that an additional 5,000 common shares have been issued by the Company in exchange for €7,000 as the result of the exercise of warrants by some employees and consultants of the Company.

As a result of this transaction, Ablynx now has 43,709,895 shares outstanding.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies ®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact: Ablynx:

Dr Edwin Moses

Chairman and CEO

t: +32 (0)9 262 00 07

m: +44 (0)7771 954 193 /

+32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Marieke Vermeersch Investor Relations Manager t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: marieke.vermeersch@ablynx.com

M:Communications:

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson t: +44 207 920 2330

e: ablynx@mcomgroup.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward - looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the
Company nor its advisers or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
09/15 ABLYNX : 15/09/2016 ablynx receives transparency notification from oppenheimer f..
09/15 ABLYNX : Receives transparency notification from oppenheimer funds, inc.
09/06 ABLYNX : 06/09/2016 ablynx receives transparency notification from gam holding a..
09/06 ABLYNX : Receives transparency notification from gam holding ag, gam internation..
08/25 ABLYNX : 25/08/2016 ablynx announces 2016 half-year results and year-to-date bus..
08/25 ABLYNX : Announces 2016 half-year results and year-to-date business update
08/22ABLYNX NV : half-yearly earnings release
08/17 ABLYNX : 17/08/2016 ablynx will announce its 2016 half year results with webcast..
08/17 ABLYNX : Will announce its 2016 half year results with webcast on 25 august 2016
08/12 ABLYNX : Receives transparency notification from adrianus van herk andvan herk i..
More news
Sector news : Biotechnology & Medical Research - NEC
04:45pDJPfizer Throws Out Plan to Split Into Two Companies
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/29 Why Abbvie Won't Pull A Galapagos On Ablynx
08/25 Ablynx, My Favorite Belgian (Biotech) Stock
08/25 Ablynx's (ABLYF) CEO Edwin Moses on Q2 2016 Results - Earnings Call Transcrip..
08/25 Ablynx NV 2016 Q2 - Results - Earnings Call Slides
08/25 Ablynx NV reports H1'16 results
Advertisement
Financials (€)
Sales 2016 104 M
EBIT 2016 -5,93 M
Net income 2016 9,00 M
Finance 2016 39,1 M
Yield 2016 -
P/E ratio 2016 218,81
P/E ratio 2017
EV / Sales 2016 6,48x
EV / Sales 2017 16,5x
Capitalization 716 M
More Financials
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Full-screen chart
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 18,2 €
Spread / Average Target 55%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Peter John Fellner Chairman
Wim Ottevaere Chief Financial Officer
Antonin Rollet de Fougerolles Chief Scientific Officer
Robert K. Zeldin Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX-26.12%803
INCYTE CORPORATION-17.95%16 728
CELLTRION, INC.--.--%11 664
LONZA GROUP AG13.18%10 059
QUINTILES TRANSNATIONA..15.66%9 453
SEATTLE GENETICS, INC.24.40%7 845
More Results